Core Viewpoint - Zimmer Biomet has completed the acquisition of Paragon 28, enhancing its position in the rapidly growing foot and ankle orthopedic market [1][5]. Group 1: Acquisition Details - The acquisition was finalized on April 21, 2025, under a merger agreement dated January 28, 2025 [5]. - Each outstanding common share of Paragon 28 was converted into $13.00 in cash and a contingent value right (CVR) worth up to $1.00 per share based on revenue milestones [6]. - Following the acquisition, Paragon 28 became a wholly-owned subsidiary of Zimmer Biomet, and its shares were delisted from the New York Stock Exchange [6][7]. Group 2: Strategic Benefits - The transaction strengthens Zimmer Biomet's offerings in the foot and ankle segment, leveraging Paragon 28's technology and sales organization [3]. - It complements Zimmer Biomet's existing fracture, trauma, and joint replacement portfolios, creating a dedicated sales channel for foot and ankle products [3]. - The acquisition is expected to drive growth in a ~$5 billion foot and ankle industry, which is projected to grow at high-single digits [4]. Group 3: Market Positioning - The acquisition enhances Zimmer Biomet's global footprint and infrastructure, facilitating adoption and growth in both U.S. and international markets [4]. - It accelerates penetration into the fast-growing Ambulatory Surgery Center (ASC) space, aligning with industry trends [4].

WARSAW, Ind., April 10, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its first quarter earnings conference call will be webcast on Monday, May 5, 2025, at 8:30 a.m. ET. A news release detailing the quarterly results will be made available that day at 6:30 a.m. ET. The live audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. It will be available for replay following the conference call. Individuals in the ...

Zimmer Biomet’s (ZBH) strategic priorities, new product launches and focus on international expansion bolster our confidence in this stock. Yet, the difficult macroeconomic situation and leveraged capital structure are concerning. The stock carries a Zacks Rank #3 (Hold).Favorable Factors For ZBHDespite challenging market conditions in the form of pricing pressure, the last few quarters witnessed gradual stability in the global musculoskeletal market with better-than-expected sales growth in certain geograp ...

Expanding Thoracic Portfolio With the CE Mark, Zimmer Biomet will make the RibFix Advantage Fixation System available in the European Economic Area (EEA) and other markets that recognize the CE Mark. RibFix Advantage Fixation System For more information on the RibFix Advantage Fixation System watch the animation. About Zimmer Biomet With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues t ...

Zimmer Biomet Holdings, Inc. (ZBH) is participating in the ongoing American Academy of Orthopaedic Surgeons (AAOS) 2025 Annual Meeting in San Diego, from March 10-14. Here, the company is highlighting advancements in hip, knee, and upper extremity reconstruction, as well as its latest ambulatory surgery center (ASC) solutions.Expanding Hip Reconstruction PortfolioAt AAOS 2025, Zimmer Biomet is presenting its comprehensive hip portfolio, with the primary focus being on the Z1 Triple-Taper Femoral Hip System, ...

Core Viewpoint - Zimmer Biomet (ZBH) is experiencing growth driven by strong procedural performance, effective execution, and innovation momentum, although the stock is facing challenges from a tough macroeconomic environment that has increased expenses [1] Group 1: Growth Factors - The company is focusing on strengthening its presence in both developed and emerging international markets, which are expected to provide long-term growth opportunities [2] - Strong revenue growth in the Asia Pacific market has been noted, supported by product launches and customer adoption [3] - The global musculoskeletal market has shown gradual stability, with improved sales growth in certain regions due to favorable demographics and increased healthcare utilization [4] Group 2: Financial Performance - In Q4 2024, Zimmer Biomet reported growth in large joints, with global sales for Knees, Hips, and S.E.T. increasing by 5.6%, 4%, and 8.4% respectively at constant exchange rates [5] - Over the past three months, ZBH shares have increased by 0.7%, while the industry has grown by 4.6% [6] Group 3: Challenges - Industry-wide staffing shortages and supply chain issues are negatively impacting growth [7] - High policy rates and geopolitical complications are affecting raw material and labor costs, as well as freight charges [8] - The company is facing reimbursement challenges in the Restorative Therapies business and acute supply challenges in Sports and Trauma, which are pressuring revenues and operating profits [8] Group 4: Cost and Margin Analysis - In Q4, the cost of products sold increased by 5.1%, and selling, general, and administrative expenses rose by 3.4%, leading to a contraction in adjusted gross margin by 123 basis points and adjusted operating margin by 43 basis points [9] - Projections indicate a 5.7% increase in the cost of products sold and a 4.2% rise in selling, general, and administrative expenses for 2025 [9] Group 5: Foreign Exchange Impact - A significant portion of Zimmer Biomet's revenues comes from Europe and Japan, where the strengthening U.S. dollar has adversely affected operations [10] - In 2024, net sales were impacted by a 1% decline due to foreign exchange rate changes, with expectations of a 1.5%-2% adverse impact on 2025 revenues [11]

Booth Spotlights Comprehensive Hip Portfolio, Newly Launched Knee and Upper Extremities Reconstructive Technologies, Including Recently Cleared Persona® Revision SoluTion™ Femur, and Debut of ZBX™ Ambulatory Surgery Center Solutions WARSAW, Ind., March 10, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that it is highlighting its diverse portfolio of orthopedic and musculoskeletal innovations at the American Academy of Orthopaedic S ...

Core Viewpoint - Zimmer Biomet Holdings, Inc. has received FDA 510(k) clearance for the Persona® Revision SoluTion™ Femur, a knee implant designed for patients with metal sensitivities, marking a significant advancement in the revision knee implant market [1][2]. Product Details - The Persona Revision SoluTion Femur is part of the Persona Revision Knee System and utilizes a proprietary surface-hardening treatment to enhance wear performance [1][2]. - This new implant is made from a proprietary Tivanium® (Ti-6Al-4V) alloy, which has over 17 years of clinical use, and is treated with the Ti-Nidium Surface Hardening Process to improve material strength and wear resistance [2][3]. - The implant will be available in standard and plus sizes to accommodate various patient needs, particularly addressing flexion instability and soft tissue balancing [2][3]. Market Context - Metal hypersensitivity affects 10-15% of the general population, with prevalence in patients with metallic implants reaching up to 25%, indicating a significant market need for alternatives to traditional metal implants [2][3]. - The Persona Revision SoluTion Femur is positioned as the first metal alternative option for patients with sensitivities to common metal allergens such as nickel, cobalt, and chromium [2][3]. Company Overview - Zimmer Biomet is recognized as a global leader in medical technology, focusing on maximizing mobility and improving health through innovative products and integrated digital technologies [3][4]. - The company has a legacy of over 90 years in the industry, emphasizing a culture of evolution and innovation to deliver high-quality solutions [4].

Core Insights - Zimmer Biomet Holdings, Inc. has appointed Kristen Cardillo as Senior Vice President and Chief Communications Officer, effective March 10, 2025, to enhance its global communications strategy and stakeholder engagement [1][2] Group 1: Appointment Details - Kristen Cardillo will report to President and CEO Ivan Tornos and is expected to amplify Zimmer Biomet's innovation narrative and strengthen brand engagement in the MedTech industry [2] - Cardillo previously served as Vice President of Corporate Communications at 10x Genomics and held significant roles at Becton, Dickinson and Company, CareFusion, and Cardinal Health, showcasing her extensive experience in corporate communications [2][3] Group 2: Company Overview - Zimmer Biomet is recognized as a global leader in medical technology, focusing on maximizing mobility and improving health through innovative products and integrated digital and robotic technologies [4][5] - The company has over 90 years of experience and is committed to delivering high-quality solutions to patients and healthcare providers [5]

Company Overview - Zimmer Biomet is a global leader in medical technology with a focus on maximizing mobility and improving health through innovative products and integrated digital and robotic technologies [2][3] - The company has over 90 years of experience and is committed to delivering high-quality solutions to patients and providers [3] Upcoming Event - Zimmer Biomet management will present at the 27th Annual Barclays Healthcare Conference on March 13, 2025, at 9:30 a.m. ET [1] - A live webcast of the presentation will be available on Zimmer Biomet's Investor Relations website, with an archived replay following the conference [1]